Recreational use of AM-2201 in the United States has led to it being specifically listed in a proposed 2011 amendment to the [[Controlled Substances Act]], aiming to add a number of synthetic drugs into [[Controlled Substances Act#Schedule I controlled substances|Schedule I]].<ref>[https://www.gpo.gov/fdsys/pkg/BILLS-112hr1254ih/pdf/BILLS-112hr1254ih.pdf Synthetic Drug Control Act of 2011].  H.R. 1254, 112th Congress, 1st Session (2011).</ref> The [[acute toxicity]] and long term side effects associated with the use of AM-2201 are acute kidney failure, brain damage, strokes, convulsions, seizures, rhabdomyolysis, and death.<ref>[https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm Acute Kidney Injury Associated with Synthetic Cannabinoid Use, Multiple States, 2012].  CDC morbitidy and mortality weekly report 2012.</ref><ref>[https://www.forbes.com/sites/melaniehaiken/2013/06/29/spice-or-synthetic-marijuana-may-cause-psychosis-brain-and-kidney-damage/#326aa1a438ab Forbes Synthetic Marijuana May Cause Psychosis, Brain and Kidney Damage]. Forbes report, Synthetic Marijuana Linked to Psychosis, Brain, and Kidney Damage. 2013</ref><ref>{{cite journal | url=http://clinicalschizophrenia.org/doi/10.3371/CSRP.DUDE.031513 | title=Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use | author1=Dante Durand | author2=Leticia L. Delgado | author3=Dhizarah Matus de la Parra-Pellot | author4=Diana Nichols-Vinueza | journal=Clinical Schizophrenia & Related Psychoses | date=January 2015 | volume=8 | issue=4 | pages=205-208 | doi=10.3371/CSRP.DUDE.031513 | pmid=23518784}}</ref><ref>[http://www.bgdailynews.com/news/testing-shows-h-incense-can-severely-damage-organs/article_b88b274d-d64f-55c1-89b1-12077848a302.html Bowling Green Daily News Report 2011].  Bowling Green Daily News Report, 2011</ref><ref>[http://phys.org/news/2013-10-dangers-fake-marijuana-spice-k2.html Phys.org Report 2013].  Phys.org Website, 2013</ref>

 
AM-2201 is a [[full agonist]] for [[cannabinoid receptor]]s. Affinities are: with a [[Dissociation constant|''K''<sub>i</sub>]] of 1.0&nbsp;nM at [[Cannabinoid receptor 1|CB<sub>1</sub>]] and 2.6&nbsp;nM at [[Cannabinoid receptor 2 (macrophage)|CB<sub>2</sub>]].<ref name="WO 2001 28557 A1">{{Ref patent2 | country = WO | number = 0128557 | status = granted | title = Cannabimimetic indole derivatives | pubdate = 2001-04-26 | gdate = 2001-06-07 | pridate= 1999-10-18 | inventor = Makriyannis A, Deng H | assign1= }}</ref> The 4-methyl [[Functional analog (chemistry)|functional analog]] [[MAM-2201]] probably has similar affinities.{{or|date=June 2015}} AM-2201 has an EC<sub>50</sub> of 38&nbsp;nM for human CB<sub>1</sub> receptors, and 58&nbsp;nM for human CB<sub>2</sub> receptors.<ref name="ACS 2015">{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00107 | date=August 2015 | first1=S. D. | first10=M. | first11=M. | first12=I. S. | first13=M. | first2=J. | first4=A. | last5=Longworth | first5=M. | last6=Wilkinson | first6=S. M. | last1=Banister | last11=Connor | last12=McGregor | last13=Kassiou | title=Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 | last2=Stuart | last3=Kevin | first3=R. C. | last4=Edington | last7=Beinat | first7=C. | last8=Buchanan | first8=A. S. | last9=Hibbs | first9=D. E. | journal=ACS Chemical Neuroscience | last10=Glass | volume=6 | issue=8 | pages=1445–1458 | doi=10.1021/acschemneuro.5b00107 | pmid=25921407}}</ref> AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3&nbsp;mg/kg, comparable to the potency of [[JWH-018]] in rats, suggesting potent cannabinoid-like activity.<ref name = "ACS 2015" />
